New data presented today reveals that the PanCan nodule
management protocol demonstrates superior performance in triaging
lung cancer screening participants compared to the LungRADSv1.1
approach. Specifically, PanCan showed improved risk stratification
and reduced the number of low-dose computed tomography (CT) scans
required.
SAN
DIEGO, Sept. 8, 2024 /PRNewswire-PRWeb/ -- PanCan
Nodule Management Protocol More Effective Than LungRADS v 1.1
Method
"This approach shows improved
identification of low and high-risk individuals and our findings
suggest that adopting the PanCan protocol could streamline lung
cancer screening and management processes." -- Dr. Annette McWilliams.
New data presented today reveals that the PanCan nodule
management protocol demonstrates superior performance in triaging
lung cancer screening participants compared to the LungRADS v 1.1
approach. Specifically, PanCan showed improved risk stratification
and reduced the number of low-dose computed tomography (CT) scans
required.
The research was reported by Dr. Annette
McWilliams, Fiona Stanley Hospital, Australia at the International Association for
the Study of Lung Cancer 2024 World Conference on Lung Cancer.
The PanCan nodule protocol utilises a risk-based approach for
triaging participants at the point of screening entry. This model
potentially simplifies management by reducing the need for frequent
LDCT scans when prior imaging is unavailable. Lung-RADS is a
quality assurance tool designed to standardize lung cancer
screening CT reporting and management recommendations, reduce
confusion in lung cancer screening CT interpretations, and
facilitate outcome monitoring.
Effective management of pulmonary nodules detected through
low-dose computed tomography screening is crucial for early lung
cancer detection and treatment. Traditionally, management
strategies have relied on baseline measurements and follow-up
imaging. The PanCan approach, unique in its use for biennial
screening triage, was compared to the LungRADS v 1.1 approach in
this study.
This study evaluated participants from the International Lung
Screen Trial who had baseline LDCT scans between August 2016 and July
2021, and who either completed at least two years of
follow-up or had a confirmed lung cancer diagnosis. Participants
were managed according to the PanCan protocol, and their outcomes
were compared to the LungRADS v 1.1 approach. The analysis included
a total of 4,494 participants, with cancer diagnoses tracked until
May 30, 2024. The study compared the
risk categories for both protocols and assessed cancer detection
rates and stage distribution at 12 and 24 months.
Out of 4,494 participants, lung cancer was detected in 184
individuals over a mean follow-up period of 57.9 months, with 109
cases identified within the first two years. The PanCan protocol
was associated with fewer referrals for diagnostic workup at
screening entry (2.8 percent vs. 7.4 percent for LungRADS v 1.1)
and demonstrated a significantly better positive predictive value
(PPV) for malignancy in high-risk categories (48.0 percent vs. 18.1
percent, P less than 0.00001). Compared to PanCan, the LungRADS v
1.1 approach required 2.63 times as many positive scans to find the
same number of lung cancers. The proportion of Stage I disease at
12 and 24 months was similar between the two approaches. Notably,
the PanCan protocol enabled triage of 75 percent of participants
with lower risk of lung cancer to biennial screening, resulting in
3,381 fewer LDCT scans without compromising the lung cancer stage
distribution. The protocol also reduces the number of participants
who require specialist referral for diagnostic workup of suspicious
lesions.
"This approach shows improved identification of low and
high-risk individuals and our findings suggest that adopting the
PanCan protocol could streamline lung cancer screening and
management processes," said Dr. McWilliams.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC)
is the only global organization dedicated solely to the study of
lung cancer and other thoracic malignancies. Founded in 1974, the
association's membership includes more than 10,000 lung cancer
specialists across all disciplines in over 100 countries, forming a
global network working together to conquer lung and thoracic
cancers worldwide. The association also publishes the Journal of
Thoracic Oncology, the primary educational and informational
publication for topics relevant to the prevention, detection,
diagnosis, and treatment of all thoracic malignancies.
About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world's largest
meeting dedicated to lung cancer and other thoracic malignancies,
attracting nearly 7,000 researchers, physicians and specialists
from more than 100 countries. The goal is to increase awareness,
collaboration and understanding of lung cancer, and to help
participants implement the latest developments across the globe.
The conference will cover a wide range of disciplines and unveil
several research studies and clinical trial results.
Media Contact
Chris Martin, IASLC, 6306702745,
cmartin@davidjamesgroup.com, www.iaslc.org
View original content to download
multimedia:https://www.prweb.com/releases/pancan-nodule-management-protocol-more-effective-than-lungradsv1-1-method-302241248.html
SOURCE IASLC